Dilated Cardiomyopathy Therapeutics Market Expected to Reach USD 0.33 billion Globally in 202016 Feb 2016
According to a new market report published by Transparency Market Research “[Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” the global dilated cardiomyopathy market was valued at USD 651.0 million in 2013 and is estimated to reach USD 328.6 million in 2020 declining at a CAGR of (7.0%)from 2014 to 2020.
The incidence of dilated cardiomyopathy cases worldwide is poorly recorded as majority of the cases are either misdiagnosed or undiagnosed. The dilated cardiomyopathy therapeutics market has been segmented by drug class and geography. North America, Europe, Asia Pacific and Rest of the World constitute the four geographies of dilated cardiomyopathy market. At the global level, North America was the largest market for dilated cardiomyopathy therapeutics in 2013 followed by Europe. This is majorly attributed to high prevalence of congestive heart failure cases followed by increased rate of diagnosis in these regions. According to data enumerated by the U.S. Centers for Disease Control and Prevention, every year around 5.1 million people are affected by heart failure, of which, about 550,000 patients are newly diagnosed every year. It is also identified that post diagnosis of heart failure, the life expectancy of the patients is around 5 years.
The detailed TOC of the report can be browsed at:
The increasing number of heart failure cases is directly proportional to the increase in national heart failure costs. For instance, according to a research paper published in 2011 by the American Heart Association, in the U.S., national heart failure costs are around USD 32 billion annually, which includes cost of medication and several healthcare services. Thus, increasing heart failure costs will negatively impact economic growth. Furthermore, owing to increasing number of cases, the Department of Health and Human Services implemented a national initiative in September 2011. The main aim of this initiative was the prevention of 1 million heart attacks and strokes by the year 2017. Such initiatives have further ensured an enhanced diagnosis rate and better management of cardiac disorders. Dilated cardiomyopathy accounts for one of the major causes of heart failure.
In the U.S. every year dilated cardiomyopathy causes around 10,000 deaths and around 46,000 hospitalizations. Furthermore, the incidence of pediatric cardiomyopathy in the U.S. is six per million children each year. In Europe, annual incidence of DCM is about five to eight people per 100,000 and it causes around 10,000 deaths each year in European countries. Hence, all these statistics indicate an increasing demand for effective treatment options for dilated cardiomyopathy in these regions.
A sample of the report in PDF obtained by visiting:
The Asia Pacific dilated cardiomyopathy therapeutics market will record the highest growth rate during the forecast period from 2014 to 2020; the major reason being increasing vulnerability towards heart failure linked to increasing obesity and growing presence of generic drug manufacturers in this region. Followed by Asia Pacific, Rest of the World (RoW) has the second highest growth rate owing to increasing patient population along with steady increase in rate of diagnosis. Despite the high demand for treatment in North America and Europe, the North America dilated cardiomyopathy therapeutics market will record lowest growth rate due to a series of patent expirations and increasing preference for long lasting treatment options such as medical devices.
Factors such as increasing rate of diagnosis for DCM followed by rising investment by market players towards developing drugs targeted against DCM will favor market growth. On the other hand, factors such as increasing preference for alternative therapies such as medical devices and gene therapy along with increasing side effects of oral medications might hamper market growth. The dilated cardiomyopathy therapeutics market provides lucrative growth opportunities for new entrants as well as established market players to commercialize DCM drugs.
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
Angiotensin-converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Dilated cardiomyopathy therapeutics market, by pipeline drugs
Dilated cardiomyopathy therapeutics market, by geography
Rest of the World (RoW)
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453